scholarly journals Clinical investigation into the initial diagnosis and treatment of 1,168 lung cancer patients

2014 ◽  
Vol 9 (2) ◽  
pp. 563-568 ◽  
Author(s):  
QIAN SHAO ◽  
JIANBIN LI ◽  
FENGXIANG LI ◽  
SUZHEN WANG ◽  
WEI WANG ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Clinical Investigation ◽  
Initial Diagnosis ◽  
Diagnosis And Treatment ◽  
Lung Cancer Patients

The pathway to diagnosis and treatment for surgically managed lung cancer patients

2019 ◽  
Author(s):  
Victoria White ◽  
Rebecca J Bergin ◽  
Robert J Thomas ◽  
Kathryn Whitfield ◽  
David Weller
Keyword(s):  
Lung Cancer ◽  
Primary Care ◽  
Cancer Patients ◽  
Secondary Care ◽  
Primary Care Physicians ◽  
Treatment Time ◽  
Early Stage ◽  
Diagnosis And Treatment ◽  
Early Stage Disease ◽  
Lung Cancer Patients

Abstract Background Most lung cancer is diagnosed at an advanced stage, resulting in poor survival. This study examined diagnostic pathways for patients with operable lung cancer to identify factors contributing to early diagnosis. Methods Surgically treated lung cancer patients (aged ≥40, within 6 months of diagnosis), approached via the population-based Cancer Registry, with their primary care physicians (PCPs) and specialists completed cross-sectional surveys assessing symptoms, diagnostic route (symptomatic or ‘investigation’ of other problem), tests, key event dates and treatment. Time intervals to diagnosis and treatment were determined, and quantile regression examined differences between the two diagnostic routes. Cox proportional hazard regression analyses examined associations between survival and diagnostic route adjusting for stage, sex and age. Results One hundred and ninety-two patients (36% response rate), 107 PCPs and 55 specialists participated. Fifty-eight per cent of patients had a symptomatic diagnostic route reporting an average of 1.6 symptoms, most commonly cough, fatigue or haemoptysis. Symptomatic patients had longer median primary care interval than ‘investigation’ patients (12 versus 9 days, P < 0.05) and were more likely to report their PCP first-ordered imaging tests. Secondary care interval was shorter for symptomatic (median = 43 days) than investigation (median = 62 days, P < 0.05) patients. However, 56% of all patients waited longer than national recommendations (6 weeks). While survival estimates were better for investigation than symptomatic patients, these differences were not significant. Conclusion Many operable lung cancer patients are diagnosed incidentally, highlighting the difficulty of symptom-based approaches to diagnosing early stage disease. Longer than recommended secondary care interval suggests the need for improvements in care pathways.

scholarly journals Pulmonary Micro-Ecological Changes and Potential Microbial Markers in Lung Cancer Patients

2021 ◽  
Vol 10 ◽  
Author(s):  
Zhuonan Ran ◽  
Jiexing Liu ◽  
Fen Wang ◽  
Caiyan Xin ◽  
Bin Xiong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Bacterial Species ◽  
Diagnosis And Treatment ◽  
Tumor Biomarkers ◽  
Healthy Individuals ◽  
Lung Cancer Patients ◽  
Ecological Changes ◽  
The Relationship ◽  
Potential Use

The relationship between the microbiome and disease has been investigated for many years. As a highly malignant tumor, biomarkers for lung cancer are diverse. However, precision of these biomarkers has not yet been achieved. It has been confirmed that lung microecology changes in lung cancer patients compared with healthy individuals. Furthermore, the abundance of some bacterial species shows obvious changes, suggesting their potential use as a microbial marker for the detection of lung cancer. In addition, recent studies have confirmed that inflammation, immune response, virulence factors, and metabolism may be potential mechanisms linking the microbiome with carcinogenesis. In this review, microbiome studies of lung cancer, potential mechanisms, potential microbial markers, and the influence of the microbiome on the diagnosis and treatment of lung cancer are summarized, providing theoretical strategies for the diagnosis and treatment of lung cancer.

scholarly journals Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients

2012 ◽  
Vol 5 (1) ◽  
pp. 271-276 ◽  
Author(s):  
HEE JOUNG KIM ◽  
SEO YOUNG OH ◽  
WAN SEOP KIM ◽  
SUN JONG KIM ◽  
GWANG HA YOO ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Mutation Detection ◽  
Egfr Mutation ◽  
Clinical Investigation ◽  
Lung Cancer Patients

scholarly journals Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer

2017 ◽  
Vol Volume 10 ◽  
pp. 535-541 ◽  
Author(s):  
Qian Shao ◽  
Shanshan Liu ◽  
Wei Wang ◽  
yingjie zhang ◽  
Fengxiang Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Investigation ◽  
Stage Iv ◽  
Initial Diagnosis ◽  
Diagnosis And Treatment ◽  
Stage Iv Lung Cancer

scholarly journals LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Murong Zhou ◽  
Yi Kong ◽  
Xiaobin Wang ◽  
Wen Li ◽  
Si Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Lung Adenocarcinoma ◽  
Cancer Patients ◽  
Transmembrane Protein ◽  
Specific Antigen ◽  
Diagnosis And Treatment ◽  
Enzyme Linked Immunosorbent Assay ◽  
Lung Cancer Patients ◽  
Serum And Urine

Lung cancer has a higher incidence rate and mortality rate than all other cancers. Early diagnosis and treatment of lung cancer remain a major challenge, and the 5-year survival rate of its patients is only 15%. Basic and clinical research, especially the discovery of biomarkers, is crucial for improving the diagnosis and treatment of lung cancer patients. To identify novel biomarkers for lung cancer, we used the iTRAQ8-plex labeling technology combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) to analyze the serum and urine of patients with different stages of lung adenocarcinoma and healthy individuals. A total of 441 proteins were identified in the serum, and 1,161 proteins were identified in the urine. The levels of elongation factor 1-alpha 2, proteasome subunit alpha type, and spermatogenesis-associated protein increased significantly in the serum of patients with lung cancer compared with those in healthy controls. The levels of transmembrane protein 143, cadherin 5, fibronectin 1, and collectin-11 decreased significantly in the serum of patients with metastases compared with those of nonmetastatic lung cancer patients. In the urine of stage III and IV lung cancer patients, the prostate-specific antigen and prostatic acid phosphatase decreased significantly, whereas neutrophil defensin 1 increased significantly. The results of LC-MS/MS were confirmed by enzyme-linked immunosorbent assay (ELISA) for transmembrane protein 143, cadherin 5, fibronectin 1, and collectin-11 in the serum. These proteins may be a potential early diagnosis and metastasis biomarkers for lung adenocarcinoma. Furthermore, the relative content of these markers in the serum and urine could be used to determine the progression of lung adenocarcinoma and achieve accurate staging and diagnosis.

scholarly journals The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review

2021 ◽  
Vol 28 (6) ◽  
pp. 4247-4255
Author(s):  
Goulnar Kasymjanova ◽  
Aksa Anwar ◽  
Victor Cohen ◽  
Khalil Sultanem ◽  
Carmela Pepe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Radiation Treatment ◽  
Lung Cancer Surgery ◽  
Retrospective Chart Review ◽  
Diagnosis And Treatment ◽  
Definitive Treatment ◽  
Cancer Center ◽  
Lung Cancer Patients ◽  
The Impact

The large burden of COVID-19 on health care systems worldwide has raised concerns among medical oncologists about the impact of COVID-19 on the diagnosis and treatment of lung cancer patients. In this retrospective cohort study, we investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and during the COVID-19 era. New lung cancer diagnoses decreased by 34.7% during the pandemic with slightly more advanced stages of disease, there was a significant increase in the utilization of radiosurgery as the first definitive treatment, and a decrease in both systemic treatment as well as surgery compared to the pre-COVID-19 era. There was no significant delay in starting chemotherapy and radiation treatment during the pandemic compared to pre-COVID-19 time. However, we observed a delay to lung cancer surgery during the pandemic time. COVID-19 seems to have had a major impact at our lung cancer center on the diagnoses and treatment patterns of lung cancer patients. Many oncologists fear that they will see an increase in newly diagnosed lung cancer patients in the coming year. This study is still ongoing and further data will be collected and analyzed to better understand the total impact of the COVID-19 pandemic on our lung cancer patient population.

Sign in / Sign up

Export Citation Format

Share Document